Executive-in-Residence Scott Fisher Named CEO of CavoGene LifeSciences

February 11, 2019

Originally appeared on Crain’s Cleveland Business, Feb. 4, 2019

Regenerative medicine expert Scott J. Fisher has been named CEO of CavoGene LifeSciences, a biotech company that has licensed a novel investigational gene therapy for patients with neurodegenerative diseases.

Fisher has previously led drug development and gene therapy clinical research of multiple regenerative therapies at early-stage companies, according to the news release.

CavoGene, which will be headquartered at the Global Center for Health Innovation in Cleveland, has secured the exclusive license to SynCav1, a novel and neuron specific gene therapy, from the University California San Diego and the laboratory of Brian P. Head.